Bai, YunpengYu, Zhi-HongLiu, SijiuZhang, LujuanZhang, Ruo-YuZeng, Li-FanZhang, ShengZhang, Zhong-Yin2018-02-272018-02-272016-08-15Bai, Y., Yu, Z.-H., Liu, S., Zhang, L., Zhang, R.-Y., Zeng, L.-F., … Zhang, Z.-Y. (2016). Novel anticancer agents based on targeting the trimer interface of the PRL phosphatase. Cancer Research, 76(16), 4805–4815. https://doi.org/10.1158/0008-5472.CAN-15-23230008-5472https://hdl.handle.net/1805/15284PRL oncoproteins are phosphatases overexpressed in numerous types of human cancer. Elevated levels of PRL associate with metastasis and poor clinical outcomes. In principle, PRL phosphatases offer appealing therapeutic targets, but they remain underexplored due to the lack of specific chemical probes. In this study, we address this issue by exploiting a unique property of PRL phosphatases, namely, that they may function as homotrimers. Starting from a sequential structure-based virtual screening and medicinal chemistry strategy, we identified Cmpd-43 and several analogs which disrupt PRL1 trimerization. Biochemical and structural analyses demonstrate that Cmpd-43 and its close analogs directly bind the PRL1 trimer interface and obstruct PRL1 trimerization. Cmpd-43 also specifically blocks the PRL1-induced cell proliferation and migration through attenuation of both ERK1/2 and Akt activity. Importantly, Cmpd-43 exerted potent anticancer activity both in vitro and in vivo in a murine xenograft model of melanoma. Our results validate a trimerization-dependent signaling mechanism for PRL and offer proof-of-concept for trimerization inhibitors as candidate therapeutics to treat PRL-driven cancersen-USPublisher Policyanticancer agentsPRL phosphatasecancerArticle